Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMZ4I03)

Drug Name
CART-meso-19 T cells Drug Info
Indication
Disease Entry ICD 11 Status REF
Pancreatic cancer 2C10 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMZ4I03

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]
Mesothelin (MSLN) TT4RXME MSLN_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
B-lymphocyte surface antigen B4 (CD19) DTT CD19 5.758 6.211 6.083 5.396
Mesothelin (MSLN) DTT MSLN -0.515 2.233 -0.152 0
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Pancreatic cancer
ICD Disease Classification 2C10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer